A Randomized, Phase 2, Placebo-Controlled, Double-Blinded Study With and Without Enzastaurin in Combination With Paclitaxel and Carboplatin as First-Line Treatment, Followed by Maintenance Treatment in Advanced Ovarian Cancer

Trial Profile

A Randomized, Phase 2, Placebo-Controlled, Double-Blinded Study With and Without Enzastaurin in Combination With Paclitaxel and Carboplatin as First-Line Treatment, Followed by Maintenance Treatment in Advanced Ovarian Cancer

Completed
Phase of Trial: Phase II

Latest Information Update: 20 Aug 2014

At a glance

  • Drugs Enzastaurin (Primary) ; Carboplatin; Paclitaxel
  • Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Biomarker; Therapeutic Use
  • Sponsors Eli Lilly
  • Most Recent Events

    • 29 Jul 2013 Results published in the Journal of Clinical Oncology.
    • 29 Jul 2013 Primary endpoint 'Progression-free-survival-duration' has not been met.
    • 25 Jul 2012 Actual end date (1 Jul 2012) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top